A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib; Imatinib Mesylate

Criteria

Inclusion Criteria:

• Diagnosis of accelerated phase or blast phase CML or Ph+ ALL

• Intolerant or resistant to imatinib mesylate

• 18 years of age or older

• ECOG performance 0-2 (greater than 50% of time out of bed)

• Adequate liver and kidney function

Exclusion Criteria:

• Pregnant or breastfeeding females

• History of significant cardiac disease

• History of significant bleeding disorder (not CML)

• Prisoners